MX2022005828A - Composicion y metodo para tratamiento de canceres hematologicos. - Google Patents
Composicion y metodo para tratamiento de canceres hematologicos.Info
- Publication number
- MX2022005828A MX2022005828A MX2022005828A MX2022005828A MX2022005828A MX 2022005828 A MX2022005828 A MX 2022005828A MX 2022005828 A MX2022005828 A MX 2022005828A MX 2022005828 A MX2022005828 A MX 2022005828A MX 2022005828 A MX2022005828 A MX 2022005828A
- Authority
- MX
- Mexico
- Prior art keywords
- mammalian subject
- pharmaceutically acceptable
- cytotoxic agent
- cancer
- hematologic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe un método para tratar a un sujeto mamífero que tiene células cancerosas hematológicas no tumorales. El método comprende los pasos de: (A) administrar a dicho sujeto mamífero una cantidad terapéuticamente eficaz de un xanteno halogenado, una sal farmacéuticamente aceptable o un éster de alquilo de C1-C4 del mismo, como un primer agente citotóxico contra el cáncer, disuelto o disperso en un medio acuoso farmacéuticamente aceptable. El sujeto mamífero se mantiene durante un período de tiempo suficiente para inducir la muerte de células cancerosas hematológicas no tumorales. Una administración contemplada normalmente se repite. Un método de tratamiento contemplado también puede llevarse a cabo junto con la administración a dicho sujeto mamífero de una segunda cantidad terapéuticamente eficaz de un segundo agente citotóxico contra el cáncer que actúa en forma diferencial, disuelto o disperso en un medio farmacéuticamente aceptable. El segundo agente citotóxico contra el cáncer puede ser una molécula pequeña o un anticuerpo intacto o una parte del mismo que contiene paratopo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/062184 WO2021101521A1 (en) | 2019-11-19 | 2019-11-19 | Composition and method for treating hematologic cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005828A true MX2022005828A (es) | 2022-07-04 |
Family
ID=75980032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005828A MX2022005828A (es) | 2019-11-19 | 2019-11-19 | Composicion y metodo para tratamiento de canceres hematologicos. |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2023506609A (es) |
| AU (1) | AU2019474803A1 (es) |
| CA (1) | CA3158221A1 (es) |
| MX (1) | MX2022005828A (es) |
| WO (1) | WO2021101521A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| KR20140038382A (ko) * | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
| CN109689056A (zh) * | 2016-08-01 | 2019-04-26 | 亚尼塔公司 | 用于治疗癌症的组合 |
-
2019
- 2019-11-19 AU AU2019474803A patent/AU2019474803A1/en active Pending
- 2019-11-19 WO PCT/US2019/062184 patent/WO2021101521A1/en active Application Filing
- 2019-11-19 CA CA3158221A patent/CA3158221A1/en active Pending
- 2019-11-19 JP JP2022555613A patent/JP2023506609A/ja active Pending
- 2019-11-19 MX MX2022005828A patent/MX2022005828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021101521A1 (en) | 2021-05-27 |
| AU2019474803A2 (en) | 2022-07-14 |
| CA3158221A1 (en) | 2021-05-27 |
| AU2019474803A1 (en) | 2022-05-26 |
| JP2023506609A (ja) | 2023-02-16 |
| AU2019474803A8 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dilda et al. | Arsenical-based cancer drugs | |
| FI113522B (fi) | Menetelmä natriumhyaluronaattia sisältävien formulaatioiden valmistamiseksi | |
| JOP20210073A1 (ar) | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| WO2020126620A3 (en) | Improved antibody-oligonucleotide conjugate | |
| HRP20170785T1 (hr) | Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti | |
| MX2022009044A (es) | Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. | |
| WO2020236825A3 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| Smith et al. | Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells | |
| SK137996A3 (en) | Cancer treatment and metastasis prevention | |
| EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
| IL300151A (en) | Combinations for cancer treatment | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
| BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| MX2020011836A (es) | Actividad antitumoral in vitro y xenoinjerto de un xanteno halogenado contra tumores solidos pediatricos refractarios. | |
| MX2022005828A (es) | Composicion y metodo para tratamiento de canceres hematologicos. | |
| WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof | |
| DK1276482T3 (da) | Kombinationskemoterapi | |
| AR122341A1 (es) | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) | |
| WO2019241641A3 (en) | Cancer treatment methods | |
| MX2021014103A (es) | Compuestos de briostatina para mejorar la inmunoterapia. | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases |